Juvenescence

CompanyIsle of ManFounded 2016

Juvenescence develops 5 assets, the furthest in phase 1 (PAI-1 Inhibitor). Mostly antibody acting on CD38; based in Isle of Man, founded in 2016.

5
Assets
Furthest stage: Phase 1
Raised: US$228.5m; 0
Trials: 0
Signals

Pipeline

5

PAI-1 Inhibitor
Inhibits PAI-1.
Phase 1
CD38 Inhibitor
Inhibits CD38.
Stage not known, CD38
GDF-15 mAb
Targets GDF-15.
Stage not known, Antibody

2 more assets

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Funding rounds and grants4
Deals2
People17